Is rituximab effective in acquired von Willebrand syndrome?

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 967-968

  Mazoyer, Elisabeth ^a   Fain, Olivier ^a,c   Dhote, Robin ^b,c   Laurian, Yves ^b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Acquired von Willebrand syndrome; Intravenous immunoglobulin; Rituximab

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FACTANE; IMMUNOGLOBULIN; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILFACTIN;

ADULT; AGED; ANEMIA; CASE REPORT; HEMATEMESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

ADULT; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; TREATMENT FAILURE; VON WILLEBRAND DISEASES;

EID: 60649109915     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07538.x     Document Type: Letter

References (9)

1. Agarwal, N., Klix, M.M. Burns, C.P. (2004) Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammapathy of undetermined significance. Annals of Internal Medicine, 141, 83 84.
2. Federici, A.B. (2008) Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? Journal of Thrombosis and Haemostasis, 6, 565 568.
3. Federici, A.B., Stabile, F., Castaman, G., Canciani, M.T. Manucci, P.M. (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood, 92, 2707 2711.
4. Federici, A.B., Rand, J.H., Bucciarelli, P., Budde, U., van Genderen, P.J.J., Mohri, H., Meyer, D., Rodeghiero, F. Sadler, J.E. (2000) Acquired von Willebrand syndrome: data from an international registry. Thrombosis and Haemostasis, 84, 345 349.
5. Grimaldi, D., Bartolucci, P., Gouault-Heilmann, M., Martin-Toutin, I., Khellaf, M. Godeau, B. (2008) Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS) - associated acquired von Willebrand syndrome. Thrombosis and Haemostasis, 99, 782 783.
6. Moll, S., Fuller, III., E., Cassara, J. Rick, M.E. (2003) Acquired von Willebrand disease not responding to rituximab. Journal of Thrombosis and Haemostasis, 1 (Suppl. 1 Abstract CD050.
7. Stachnik, J.M. (2006) Rituximab in the treatment of acquired hemophilia. Annals of Pharmacotherapy, 40, 1151 1157.
8. Tiede, A., Priesack, J., Werwitzke, S., Bohlmann, K., Oortwijn, B., Lenting, P., Eisert, R., Ganser, A. Budde, U. (2008) Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-center cohort study. Journal of Thrombosis and Haemostasis, 6, 569 576.
9. Veyradier, A., Jenkins, C., Fressinaud, E. Meyer, D. (2000) Acquired von Willebrand syndrome: from pathophysiology to management. Thrombosis and Haemostasis, 84, 175 182.